| Literature DB >> 35237567 |
Ivy Guan1,2, Kayla Williams1,2, Joanna Shu Ting Liu2,3, Xuyu Liu1,2.
Abstract
Cells employ post-translational modifications (PTMs) as key mechanisms to expand proteome diversity beyond the inherent limitations of a concise genome. The ability to incorporate post-translationally modified amino acids into protein targets via chemical ligation of peptide fragments has enabled the access to homogeneous proteins bearing discrete PTM patterns and empowered functional elucidation of individual modification sites. Native chemical ligation (NCL) represents a powerful and robust means for convergent assembly of two homogeneous, unprotected peptides bearing an N-terminal cysteine residue and a C-terminal thioester, respectively. The subsequent discovery that protein cysteine residues can be chemoselectively desulfurized to alanine has ignited tremendous interest in preparing unnatural thiol-derived variants of proteogenic amino acids for chemical protein synthesis following the ligation-desulfurization logic. Recently, the 21st amino acid selenocysteine, together with other selenyl derivatives of amino acids, have been shown to facilitate ultrafast ligation with peptidyl selenoesters, while the advancement in deselenization chemistry has provided reliable bio-orthogonality to PTMs and other amino acids. The combination of these ligation techniques and desulfurization/deselenization chemistries has led to streamlined synthesis of multiple structurally-complex, post-translationally modified proteins. In this review, we aim to summarize the latest chemical synthesis of thiolated and selenylated amino-acid building blocks and exemplify their important roles in conquering challenging protein targets with distinct PTM patterns.Entities:
Keywords: chemical protein synthesis; cysteine; deselenization; desulfurization; peptide ligation; protein modification; semisynthesis; unnatural amino acid
Year: 2022 PMID: 35237567 PMCID: PMC8883728 DOI: 10.3389/fchem.2021.826764
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
SCHEME 1(A) Native chemical ligation; (B) Kinetically-controlled ligation;(C) Transforming peptide hydrazide to peptide thioester via oxidation and thiolysis; (D) Protein thioesterification via thiolysis of intein tag; (E) Sortase-mediated peptide ligation; (F) One-pot selenocystine-selenoester ligation-deselenization chemistry.
SCHEME 2(A) Preparation of β-thiol Leu via Brik’s route; (B) Preparation of β-thiol Leu via Danishefsky’s route; (C) Synthesis of β-selenol Leu via Payne’s route.
SCHEME 3(A) Synthesis of γ-thiol derived Pro; (B) Synthesis of γ-selenylated Pro.
SCHEME 4(A) Synthesis of β-thiolated Phe via Easton's route. (B) Synthesis of β-thiolated Phe via Payne's route. (C) Synthesis of β-selenylated Phe reported by Malins et al.; (D) Asymmetric synthesis of β-selenylated Phe via a cyclic sulfamidate intermediate reported by Baig et al.
SCHEME 5(A) Synthesis of γ-thiolated Lys reported by Liu and co-workers; (B) Synthesis of δ-thiolated Lys via Brik's route; (C) Synthesis of γ-thiolated Lys reported by Merkx et al.
SCHEME 6Synthesis of two differentially functionalized γ-selenol Lys reported by Metanis and co-workers.
SCHEME 7(A) Synthesis of γ-thiol derived Val; (B) Synthesis of γ-thiol derived Thr; (C) Synthesis of γ-thiol derived Ile.
SCHEME 8Synthesis of (A) β-thiolated Asp and (B) γ-thiolated Glu via electrophilic sulfenylation chemistry.
SCHEME 9(A) Synthesis of β-thiol derived Asn via electrophilic sulfenylation chemistry; (B) Tan’s route to prepare β-thiol derived Asp; (C) Synthesis of β-selenol derived Asp and γ-selenol derived Glu via electrophilic selenylation chemistry.
SCHEME 10(A) Electrophilic sulfeylation of peptidyl Trp; (B) Synthesis of β-thiol derived Arg based on Garner’s aldehyde; (C) Preparation of γ-thiol derived Gln via a Passerini three-component reaction.
SCHEME 11(A) Preparation of pivalaldehyde-masked dehydrocysteine and dehydroselenocysteine; (B) Wang’s route to β-thiol/selenol derived amino acids via photoredox-catalyzed asymmetric Giese reactions.
SCHEME 12(A) Synthesis of sulfated anophelin variants via one-pot ligation-desulfurization chemistry; (B) Convergent synthesis of homogeneous glycoforms of IL-17A.
SCHEME 13Synthesis of MUC I glycopeptide using a ligation-desulfurization method.
SCHEME 14(A) Liu’s dual ligation strategy to access site-specific ubiquitination; (B) Brik’s synthesis of the di-ubiquitin library (C) Siman’s route to access Lys34-ubiquitinated H2B.
SCHEME 15(A) Payne’s route to access differentially glycosylated human IFN-γ; (B) Chemical synthesis of post-translationally sulfated UL22A via β-selenylated Leu-mediated DSL and (C) reductive diselenide-selenoester ligation.
SCHEME 16(A) Pro-Pro ligation via DSL and reductive selenium ligation chemistries; (B) Chemical synthesis of a library of sulfated anticoagulants via a DSL-deselenization manifold.
Thiol derived amino acids and the relevant synthesis examples described in this article.
| Thiolated amino acid | Synthetic strategy | Peptide and protein synthesis example | References(s) |
|---|---|---|---|
|
| 1. Aziridine ring opening | ATAD2 bromodomain region |
|
| 2. Nucleophilic displacement | |||
|
| Nucleophilic displacement | 1. Rat neuromedin U |
|
| 2. hEPO (79–166) Glycopeptide | |||
|
| 1. Nucleophilic displacement | 1. Fragment of Augurin |
|
| 2. Garner’s aldehyde | 2. Glycosylated human IFN-γ | ||
|
| Nucleophilic displacement | 1. Ubiquitinated peptide |
|
| 2. Diubiquitin and tetraubiquitin | |||
|
| Nucleophilic conjugate addition | 1. Diubiquitin |
|
| 2. Site-specific ubiquitinated H2B | |||
|
| Nucleophilic displacement | Model peptides |
|
|
| Nucleophilic displacement | Model peptides |
|
|
| C (sp3)-H activation |
|
|
|
| 1. Electrophilic sulfenylation | 1. Extracellular N-terminal domain of CXCR4 |
|
| 2. Nucleophilic displacement | 2. Sulfated anopheline proteins | ||
| 3. Glycosylated IL-17A | |||
|
| Electrophilic sulfenylation | Teriparatide |
|
|
| Electrophilic sulfenylation | Enfuvirtide |
|
|
| Electrophilic sulfenylation | Extracellular N-terminal domain of CXCR1 |
|
|
| Garner’s aldehyde | Glycosylated extracellular domain of MUC1 |
|
|
| Passerini three-component reaction | Model peptides |
|
|
| Photoredox-catalyzed asymmetric | Model peptides |
|
| Giese reaction | |||
|
| Commercially available | Tri-phosphorylated C-terminal Tau |
|
Selenol derived amino acids and the relevant synthesis examples described in this article.
| Selenolated amino acid | Synthetic strategy | Peptide and protein synthesis example | References(s) |
|---|---|---|---|
|
| Garner’s aldehyde | Sulfated UL22A |
|
|
| Nucleophilic displacement | 1. Hydroxy-proline model peptide |
|
| 2. SMR3B | |||
| 3. Lumbricin-1 | |||
|
| 1. Nucleophilic displacement | Model peptides |
|
| 2. Garner’s aldehyde | |||
|
| 1. Nucleophilic displacement | SUMOylated GCK |
|
| 2. Nucleophilic conjugate addition | |||
|
| Electrophilic sulfenylation | 1.Sulfated Hya1-3 |
|
| 2. Selenoprotein K | |||
| 3. And82, And310 and MDL2 | |||
| 4. non-modified Hya2-4 | |||
|
| Electrophilic sulfenylation | Model peptides |
|
|
| Photoredox-catalyzed asymmetric Giese reaction | Cytpchrome |
|
| Oxytocin analogues |